Phase 1 Trial of KH801 - Trial NCT06364501
Access comprehensive clinical trial information for NCT06364501 through Pure Global AI's free database. This Phase 1 trial is sponsored by Beijing Kanghong Biopharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 17 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Beijing Kanghong Biopharmaceutical Co., Ltd.
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Timeline & Enrollment
Phase 1
May 01, 2024
May 01, 2030
Primary Outcome
MTD,DLT,RP2D
Summary
KH801 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Or
 0.9% sodium chloride Injection.
 
 This study is expected to include a total of approximately 17-42 participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06364501
Non-Device Trial